SHIRLEY, N.Y., August 27, 2025 — American Regent, Inc.® has announced the commercial launch of Gvoke VialDx™ (glucagon injection), the first concentrated, ready-to-dilute liquid glucagon designed for intravenous use as a diagnostic aid during radiologic examinations. The innovation provides radiologists and clinicians with a new option to temporarily inhibit gastrointestinal motility in adult patients, enhancing diagnostic precision and workflow efficiency.
Science Significance
The introduction of Gvoke VialDx represents a significant advancement in radiological science. By providing a liquid, ready-to-dilute formulation, the product addresses limitations of lyophilized (powdered) glucagon that required reconstitution. This reduces preparation time, improves accuracy in dosing, and minimizes procedural delays during imaging. Its ability to inhibit gastrointestinal movement enhances image clarity, supporting improved diagnostic outcomes.
Regulatory Significance
The availability of Gvoke VialDx follows FDA approval as a diagnostic aid in radiologic exams. Its regulatory clearance confirms the product’s safety, efficacy, and manufacturing quality under strict U.S. guidelines. This milestone reflects the growing acceptance of ready-to-use injectable formulations that improve hospital workflows while maintaining patient safety.
Business Significance
Advertisement
For American Regent, the launch expands its branded injectable portfolio in the U.S. hospital and acute care market. By leveraging its established commercialization expertise and supply chain reliability, the company strengthens its leadership position in sterile injectables. The product also demonstrates the business value of strategic partnerships in bringing innovative formulations to market.
Patients’ Significance
For patients undergoing radiologic exams, Gvoke VialDx can significantly improve the diagnostic process. Its simplified preparation and rapid administration reduce waiting times and procedural errors. Additionally, consistent inhibition of gastrointestinal motility enables more accurate imaging, which translates into better diagnostic confidence and clinical decision-making for conditions requiring radiological evaluation.
Policy Significance
The launch underscores the need for policy frameworks that encourage innovation in diagnostic adjuncts, particularly those that improve patient safety and workflow efficiency. Policymakers may also recognize its role in reducing healthcare system burden by streamlining imaging procedures, potentially lowering costs and increasing access to advanced diagnostics in both hospital and outpatient settings.
Transaction Highlights
American Regent has officially introduced Gvoke VialDx™ (glucagon injection) in the U.S. market, marking the debut of the first concentrated, ready-to-dilute liquid glucagon available for radiological use. The product is indicated for the temporary inhibition of gastrointestinal tract motility in adult patients undergoing diagnostic imaging procedures. Supplied in single-dose vials (1 mg/0.2 mL) in 1-count and 10-count packs, Gvoke VialDx is now available for shipment. With this launch, American Regent reinforces its commitment to delivering high-quality sterile injectables that support both clinical excellence and healthcare system efficiency.
Source: American Regent Press Release
